CHELMSFORD, Mass., Nov. 8 /PRNewswire/ -- Magellan Biosciences, a leading provider of point-of-care products, automated laboratory systems, and consumables for clinical diagnostics and biomedical research, announced that its subsidiary, Dynex Technologies, will premier its new DS2(TM) System, a fully automated clinical-diagnostic workstation, at Medica 2005, to be held 16-19 November in Dusseldorf, Germany.

According to Magellan President and CEO, Robert J. Rosenthal, the DS2 is an important part of Magellan's growth strategy, representing the first of many new products in Magellan's pipeline that target the clinical-diagnostics market. "Increasingly, physicians are looking to improve health outcomes by bringing diagnostic products closer to the patient so they can get more- accurate, immediate results, and respond more-quickly with appropriate treatments or therapies. The DS2 makes this possible," said Dr. Rosenthal. "We believe that the DS2 fills a significant unmet need in the marketplace, serving the large number of near-patient and other clinical labs worldwide that would like to enhance their processes through automation, but have too- small-volume requirements to justify the investment in the systems currently on the market."

Dr. Rosenthal continued, "We want to be known as innovation leaders -- the 'go-to' company, when it comes to helping customers be successful in their current and future endeavors. We design our offerings to be well- differentiated in the marketplace as best-in-class products -- compelling purchases that customers want and need because they enable them to do their jobs easier and more effectively, whether its in a research or clinical setting. Serving our customers well and consistently exceeding their expectations will help ensure that we create a sustainable and growing business.

"Building on Dynex's renowned DSX(TM) walk-away workstation, the DS2 System has all the power and performance of the higher-capacity DSX, but is designed for the needs of demanding patient-care settings and lower-throughput clinical labs. With advanced automation and precise liquid-handling capabilities, the DS2 eliminates variations that occur with manual processes, ensuring the rigorous, repeatable analyses required in critical applications - - from immunology to infectious disease, hormone, allergy, blood-chemistry, and drugs-of-abuse testing."

Reliable, cost-effective, and easy to use and maintain, the DS2 automated workstation can process two 96-well microplates and up to 12 different assays simultaneously. An open system, the DS2 performs the entire complement of analytical steps required for virtually any ELISA immunoassay: adding samples and reagents, washing, incubation, and absorbance detection. It features the most advanced and user-friendly control system available, designed with full walk-away capability, sample ID-bar-code reading, chain-of-custody, and instrument-diagnostic features.

Dynex will be exhibiting in the North American Pavilion, Hall 3, Stand # C30-1. Dr. Rosenthal and other company executives will hold a press conference on Thursday, November 17, 2005, in room 201, north entrance to discuss the new products and Magellan Biosciences' strategy overall.

About Dynex Technologies

The Experts in Microplate Analysis, Dynex Technologies, Inc. is a leading manufacturer of microplate instrumentation incorporating advanced detection and fully automated sample handling, consumables, and accessories used in clinical diagnostics, drug discovery, biomedical research, and industrial applications worldwide. Founded in 1952, and headquartered in Chantilly, Virginia, Dynex is a wholly owned subsidiary of Magellan Biosciences. For more information, visit http://www.dynextechnologies.com.

About Magellan Biosciences

Magellan Biosciences develops point-of-care products, related consumables, and automated laboratory systems for clinical diagnostics and biomedical research worldwide. These tools enable scientists and clinicians to produce better, more-reliable results. And improved results help drive better outcomes: a new understanding of health and disease, earlier, more-accurate diagnoses -- breakthrough discoveries that can lead to novel treatments, new cures -- innovations to enhance life. Magellan serves customers through its wholly owned subsidiaries: ESA Biosciences, Dynex Technologies, and TekCel. For more information, visit http://www.magellanbio.com.